Acute myelogenous leukemia-derived SMAD4 mutations target the protein to ubiquitin-proteasome degradation

Human Mutation

Volumn 27, Issue 9, 2006, Pages 897-905

  Yang, Lei ^a,b   Wang, Ning ^a   Tang, Yi ^b   Cao, Xu ^b   Wan, Mei ^b  

^a SHIHEZI UNIVERSITY   (China)

^b University of Alabama at Birmingham   (United States)

Author keywords

TrCP1; Acute myelogenous leukemia; Protein instability; SMAD4 gene mutation; TGF ; TGFB1; Ubiquitin proteasome pathway

Indexed keywords

BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN 1; F BOX PROTEIN; GENE PRODUCT; LEUCINE; MAD HOMOLOGY 1; MAD HOMOLOGY 2; MUTANT PROTEIN; PROLINE; PROTEASOME; PROTEIN SKP1; SMAD4 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; FRAMESHIFT MUTATION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; LEUKEMIA CELL; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SMAD4 GENE; UBIQUITINATION; WILD TYPE;

ANIMALS; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CERCOPITHECUS AETHIOPS; COS CELLS; FRAMESHIFT MUTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MUTATION, MISSENSE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN;

EID: 33748344500     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20387     Document Type: Article

References (50)

1. Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth factor beta in human disease. N Engl J Med 342:1350-1358.
2. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, Draetta GF. 2003. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426:87-91.
3. DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, Kadin ME. 1997. Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc Natl Acd Sci USA 94:5877-5881.
4. Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577-584.
5. DeSalle LM, Pagano M. 2001. Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett 490:179-189.
6. Deshaies RJ. 1999. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15:435-467.
7. Fong A, Sun SC. 2002. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-κB2/p100. J Biol Chem 277:22111-22114.
8. Fortunel NO, Hatzfeld A, Hatzfeld JA. 2000. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96:2022-2036.
9. Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J. 2003. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 278:41355-41366.
10. Fuchs SY, Chen A, Xiong Y, Pan ZQ, Ronai Z. 1999. HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IκB and beta-catenin. Oncogene 18:2039-2046.
11. Fuchs SY, Spiegelman VS, Kumar KG. 2004. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene. 23:2028-2036.
12. Grzegorzewski KF, Ruscetti FW, Usui N, Damia G, Longo DL, Carlino JA, Keller JR, Wiltrout RH. 1994. Recombinant transforming growth factor beta1 and beta2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med 180:1047-1057.
13. Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, Margottin-Goguet F, Jackson PK, Yamasaki L, Pagano M. 2003. Control of meiotic and mitotic progression by the F box protein β-Trcp1 in vivo. Dev Cell 4:799-812.
14. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353.
15. Hata A, Lo RS, Wotton D, Lagna G, Massagué J. 1997. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature 388:82-87.
16. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE. 2004. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 10:1597-1604.
17. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Maki K, Ogawa S, Chiba S, Mitani K, Hirai H. 2001. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene 20:88-96.
18. Jackson PK, Eldridge AG. 2002. The SCF ubiquitin ligase: an extended look. Mol Cell 9:923-925.
19. β-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 17:3062-3074.
20. Kim S, Letterio J. 2003. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Leukemia 17:1731-1737.
21. Kurokawa M, Mitani K, Irie K, Matsuyama T, Yakahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H. 1998. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 394:92-96.
22. Lagneaux L, Delforge A, Bron D, Massy M, Bernier M, Stryckmans P. 1997. Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGF-beta receptors. Br J Haematol 97:612-620.
23. Lang V, Janzen J, Fischer GZ, Soneji Y, Beinke S, Salmeron A, Allen H, Hay RT, Ben Neriah Y, Ley SC. 2003. βTrCP-mediated proteolysis of NF-κB1 pl05 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol 23:402-413.
24. Lassot I, Segeral E, Berlioz-Torrent C, Durand H, Groussin L, Hai T, Benarous R, Margottin-Goguet F. 2001. ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(β-TrCP) ubiquitin ligase. Mol Cell Biol 21:2192-2202.
25. Lee DH, Goldberg AL. 1998. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8:397-403.
26. β-TrCP E3 ubiquitin ligase. Mol Cell Biol 24:4038-4048.
27. Liang M, Liang YY, Wrighton K, Ungermannova D, Wang XP, Brunicardi FC, Liu X, Feng XH, Lin X. 2004. Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2. Mol Cell Biol. 24:7524-7537.
28. Maniatis T. 1999. A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev 13:505-510.
29. Mantovani F, Banks L. 2003. Regulation of the discs large tumor suppressor by a phosphorylation-dependent interaction with the β-TrCP ubiquitin ligase receptor. J Biol Chem 278:42477-42486.
30. Massague J. 1998. TGF-beta signal transduction. Annu Rev Biochem 67:753-791.
31. Maurice D, Pierreux CE, Howell M, Wilentz RE, Owen MJ, Hill CS. 2001. Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability. J Biol Chem 276:43175-43181.
32. Moren A, Hellman U, Inada Y, Imamura T, Heldin CH, Moustakas A. 2003. Differential ubiquitination defines the functional status of the tumor suppressor Smad4. J Biol Chem 278:33571-33582.
33. Muerkoster S, Arlt A, Sipos B, Witt M, Grossmann M, Kloppel G, Kalthoff H, Folsch UR, Schafer H. 2005. Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 65:1316-1324.
34. Nakayama KI, Nakayama K. 2005. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 16:323-333.
35. Pickart CM. 2001. Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503-533.
36. Rooke HM, Vitas MR, Crosier PS, Crosier KE. 1999. The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression. Leukemia 13:535-541.
37. Schakowski F, Buttgereit P Mazur M, Marten A, Schottker B, Gorschluter M, Schmidt-Wolf IG. 2004. Novel non-viral method for transfection of primary leukemia cells and cell lines. Genet Vaccines Ther 2:1.
38. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA, Kern SE. 1996. DPC4 gene in various tumor types. Cancer Res 56:2527-2530.
39. Shi Y, Hata A, Lo RS, Massagué J, Pavletich NP. 1997. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 388:87-93.
40. Shimizu K, Gurdon JB. 1999. A quantitative analysis of signal transduction from activin receptor to nucleus and its relevance to morphogen gradient interpretation. Proc Natl Acad Sci USA 9:6791-6796.
41. Sui G, Soohoo C, Affare B, Gay F, Shi Y, Forrester WC, Shi Y 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99:5515-5520.
42. Sunamura M, Yatsuoka T, Motoi F, Duda DG, Kimura M, Abe T, Yokoyama T, Inoue H, Oonuma M, Takeda K, Matsuno S. 2002. Gene therapy for pancreatic cancer based on genetic characterization of the disease. J Hepatobiliary Pancreat Surg 9:32-38.
43. Tang W Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, Fuchs SY 2005. Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res 65:1904-1908.
44. Wan M, Tang Y, Tytler EM, Lu C, Jin B, Vickers SM, Shi X, Cao X. 2004. Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1. J Biol Chem 279:14484-14487.
45. β-TrCP1 controls Smad4 protein stability in pancreatic cancer cells. Am J Pathol 166:379-392.
46. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T, Osada H. 2004. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proc Natl Acad Sci USA 101:4419-4424.
47. Xu J, Attisano L. 2000. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 97:4820-4825.
48. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben Neriah Y 1998. Identification of the receptor component of the IκBα-ubiquitin ligase. Nature 396:590-594.
49. Yue J, Mulder KM. 2001. Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Ther 91:1-34.
50. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. 2004. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6:931-940.